Company Profile
Founded in 2015, VBIO Pharma is a certified high-tech enterprise and a global leader in reproductive biologics for human and animal health, with expertise in in vitro fertilization (IVF) and fertility solutions. The company is supported by leading experts in protein biologics with professional and academic backgrounds at MSD, Yale University, the University of California, Berkeley, the University of Washington, and the University of Toronto. With a team of over 200 professionals, VBIO Pharma specializes in the research, development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs), pharmaceutical formulations, veterinary medicines, intimate health products, and personal care products.
With a registered capital of RMB 65 million and a manufacturing facility covering 100,000 square meters, VBIO Pharma holds more than 50 patents in China and internationally and has extensive practical experience supporting the reproductive management of over 30 million animals, including pigs, cattle, sheep, and aquatic species. Headquartered in the Guangzhou Economic and Technological Development Zone, the company is committed to delivering world-class innovative solutions. It has received numerous qualifications and honors, including recognition as a National High-Tech Enterprise, a Guangdong Provincial Specialized, Sophisticated, Distinctive and Innovative, and a Guangzhou Leading Enterprise in Innovation and Entrepreneurship.
VBIO Pharma's technical team has extensive experience in the development of human biopharmaceuticals in China and internationally, particularly in the fields of IVF and embryo transfer. The company has independently established a world-leading technology platform for the development of innovative highly glycosylated protein therapeutics. This platform integrates key technologies, including recombinant protein engineering, long-acting protein modification, and the large-scale extraction and purification of naturally derived proteins.
Products developed using this platform demonstrate distinct competitive advantages, including well-characterized glycosylation profiles, high biological activity, and cost-efficient production. The platform has been successfully applied to the research, development, and commercialization of multiple innovative human and veterinary medicines. VBIO Pharma has developed several innovative veterinary drugs, including the world's first mammalian cell-derived long-acting follicle-stimulating hormone (FSH) product, and has been granted multiple invention patents in China and the United States.
To address reproductive challenges and improve breeding efficiency across the livestock and aquaculture industries, VBIO Pharma has developed a comprehensive portfolio of reproductive management solutions for pigs, cattle, sheep, and aquatic species, supported by Multiple product approvals. Its flagship offerings include V-OneMate®, an innovative solution designed to improve reproductive efficiency through single-service breeding in sows, as well as pioneering products such as long-acting FSH for embryo transfer in cattle and sheep.
Validated through applications by China's top 30 livestock breeding groups, VBIO Pharma's products have demonstrated the potential to significantly improve reproductive efficiency, reduce production costs, and enhance profitability, delivering substantial economic benefits to livestock producers.
Today, VBIO Pharma's product portfolio is marketed across numerous provinces and municipalities throughout China. The company has served leading agricultural and livestock enterprises, including COFCO, Wens, Muyuan, Tianbang, CP Group, and Mengniu. Ranking among the top three companies in its specialized market segment, VBIO Pharma has established a strong reputation and a recognized brand presence within the industry.









